OM
ALBO

Opaleye Management’s Albireo Pharma Inc ALBO Stock Holding History

Opaleye Management’s Portfolio ALBO Stock Details ALBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-36,500
Closed -$876K – 51
2017
Q1 		$876K Buy
+36,500
New +$794K 0.44% 38

Other funds holding ALBO

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Opaleye Management's ALBO Position: Q2 2017 in Review

Opaleye Management sold out of Albireo Pharma Inc (ALBO) in Q2 2017, closing a stake of 36,500 shares — an estimated $876K sold.

Opaleye Management first reported a position in ALBO in Q1 2017 and held it in 1 quarter. The position peaked at $876K in Q1 2017. 24 funds tracked by Wall St. Rank hold ALBO as of Q2 2017.

  • Opaleye Management reported no remaining Albireo Pharma Inc position as of Q2 2017 after selling out during the quarter.
  • Opaleye Management sold 36,500 Albireo Pharma Inc shares in Q2 2017, an estimated $876K.
  • Opaleye Management first reported a position in Albireo Pharma Inc in Q1 2017 and held it in 1 quarter.
  • Opaleye Management's Albireo Pharma Inc position peaked at $876K in Q1 2017.
  • 24 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q2 2017.

Based on Opaleye Management's 13F filing for Q2 2017, filed 14 Aug 2017.